From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 50s
Ascendis Pharma Q3 Profitability Shift
Ascendis Pharma's TransCon platform now generates €370m revenue with 72.9% YoY growth.
In brief
Ascendis Pharma's TransCon platform now generates €370m revenue with 72.9% YoY growth. Ascendis Pharma achieved €370 million in Q3 2026 revenue, marking a transition from development-stage to cash-generating operations. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Q3 2026 Results
Ascendis Pharma reported Q3 2026 revenue of €370 million, a 72.9% year-over-year increase from €214 million in Q3 2025.
Commercial Product Revenue Surge
Commercial product revenue surged 88.8% to €365.7 million, driven by YORVIPATH® generating €291 million.
Operating Profitability
Non-IFRS operating profit reached €156 million, a 271% year-over-year increase from €42 million.
Cash Flow and Share Repurchase
Operating cash flow totaled €463 million, with 1,998,999 shares repurchased for $459 million.
Investor Catalysts
Three key catalysts will define ASND investment case through 2027: EU filing decision, BioMarin dispute settlement, and YORVIPATH enrollment trajectory.
What it means
Ascendis Pharma achieved €370 million in Q3 2026 revenue, marking a transition from development-stage to cash-generating operations.
